PLATFORM

Powering the future of
immune-mediated inflammatory disease (IMID) medicines

Discovering and developing the next generation of medicines for IMIDs

PATIENT-BASED DISCOVERY

Our Clinical Discovery Engine directly addresses one of the greatest risks to health today

At IMIDomics, our discovery process begins and ends with the patients. Our Engine uses state-of-the-art discovery tools combined with the highest quality patient data, omics, analytical tools, and a deep understanding of IMIDs. Our multidimensional approach is required to characterize their multiple forms and complexity at the individual and patient group levels.

Currently FOCUSing ON eight diseases

Systemic Lupus Erythematosus

Ulcerative Colitis

Crohn’s Disease

Rheumatoid Arthritis

Psoriasis

Psoriatic Arthritis

Atopic Dermatitis

Sjögren’s Syndrome

CLINICAL DISCOVERY ENGINE

Our Engine combines the collection, generation, and analysis of data to drive more efficient drug development

CLINICAL NETWORK

The Engine begins with access to patients and their samples through our clinical network. Partnered physicians collect epidemiological and clinical data, and biological samples which are stored in the Vall d’Hebron Institute of Research (VHIR) IMID Biobank.

DATA GENERATION

Samples are subject to the most modern biomolecular analyses, generating proprietary multiomics data. These data are integrated with epidemiological and clinical data, forming the backbone of the Engine . The provenance of all our data is controlled by IMIDomics.

TARGET DISCOVERY

Our IMID experts interrogate our data using multidimensional computational approaches to inform target discovery. This leads to new disease mechanism insights, disease markers and targets, and prioritization strategies.

Development

Finally, we partner with industry leaders such as Evotec to drive drug discovery and development that can produce new medicines faster, cheaper, and with lower risks.

CLINICAL NETWORK

Our network of clinicians and academic partners give us unprecedented access to patient data and samples

Our work is enabled by an investigator network across Spain. They follow a common protocol, and data are audited and curated to ensure validity, quality, and comparability. Samples are stored in the ISO-certified IMID Biobank. Patient identity for all data and samples is anonymized prior to transfer to IMIDomics in compliance with GDPR regulations.

BIOBANK

>17,000 subjects
Cross-sectional and longitudinal
>1M sample vials of biological specimens
Every subject donates whole blood and urine
Biopsies from select subjects

Direct investigator engagement

Protocols developed in collaboration with KOLs

Epidemiological and Clinical Data

>15,000 clinical variables
>150 epidemiological variables
2M epidemiological and clinical data points collected
Collected for every subject

Selection of most informative patients

Ability to follow up with subjects

DATA GENERATION

We use the most advanced bio-analytical methods to probe mechanisms driving disease

The following data are collected and combined into a proprietary database of more than 14 terabytes which allows interrogation and analysis across all datatypes on a single-patient basis or across the whole collection of subjects.

GWAS

Bulk RNA-seq

Proteomics

Epigenetics

Single-cell data

TARGET DISCOVERY

This allows us to match the right drug target to the right patient

Our approach personalizes treatment by matching patients with the right drug targets. Using multidimensional patient data and machine learning, we uncover underlying disease processes, identify common mechanisms, and categorize patients into subgroups. This reveals new insights for target discovery and helps assess their applicability across multiple IMIDs.

Integrated, multidimensional analysis applied to reliable data yields innovative targets and relevant patient populations

Define diseases at the single cell level

Leverage genetic architecture to identify causal mechanisms

Characterization of large patient cohorts

Untangle genetic profiles to stratify patient populations

Find out more about our pipeline

DOCTIS

Decision on optimal combinatorial Therapies in IMIDs using Systems Approaches

European Union Horizon 2020 Research and Innovation Programme

Coordinator: Dr. Sara Marsal

To discover effective drug combinations to treat IMID patients based on:

Patient medical and epidemiological data
Multi-omic patient analyses
Bioinformatics
Preclinical and clinical experimentation

Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases

Powering the future ofimmune-mediated inflammatory disease (IMID) medicines

PATIENT-BASED DISCOVERY

Our Clinical Discovery Engine directly addresses one of the greatest risks to health today

Currently FOCUSing ON eight diseases

CLINICAL DISCOVERY ENGINE

Our Engine combines the collection, generation, and analysis of data to drive more efficient drug development

CLINICAL NETWORK

DATA GENERATION

TARGET DISCOVERY

Development

CLINICAL NETWORK

Our network of clinicians and academic partners give us unprecedented access to patient data and samples

BIOBANK

Epidemiological and Clinical Data

DATA GENERATION

We use the most advanced bio-analytical methods to probe mechanisms driving disease

TARGET DISCOVERY

This allows us to match the right drug target to the right patient

DOCTIS

Decision on optimal combinatorial Therapies in IMIDs using Systems Approaches

Powering the future of
immune-mediated inflammatory disease (IMID) medicines